恒瑞医药：收到两份药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-2329 tablets and SHR-4298 injection, indicating progress in its drug development pipeline [1] Group 1: Clinical Trial Approvals - The company announced that it has received the clinical trial approval notice for HRS-2329 tablets from the National Medical Products Administration [1] - Its subsidiary, Suzhou Sediya Biopharmaceutical Co., Ltd., has also received approval for SHR-4298 injection [1] Group 2: Drug Registration Application - Heng Rui Medicine announced that its innovative drug, a combination of injectable Carrelizumab and Apalutamide capsules, has had its drug registration application accepted for the first-line treatment of recurrent or metastatic cervical cancer patients [1]